Insulin-like growth factor-II: possible local growth factor in pheochromocytoma.

Pheochromocytomas, neural crest tumors, express an abundance of insulin-like growth factor-II (IGF-II). To assess further the potential for IGF-II to play an autocrine role for these tumors, we measured 1) IGF-II content by RRA in 7 pheochromocytomas and peripheral blood in these patients, 2) IGF-II receptors by Western analysis, and 3) characterized the tumor binding proteins by ligand blot studies. IGF-II levels in the tumors varied from 2.8-41 micrograms/g. Chromatography revealed that 60% of the peptide eluted as a large mol wt form of IGF-II (8.7-10 kDa); the remainder coeluted with mature peptide (7.5 kDa). This was in contrast to IGF-II levels in normal adrenal tissue (0.225 +/- 0.005 micrograms/g) or another neural crest-derived tumor, medullary carcinoma of the thyroid (0.63 +/- 0.02 micrograms/g). Serum IGF-II levels in the 7 patients with pheochromocytoma (720 +/- 71 ng/mL) were similar to those in 35 normal controls (762 +/- 69 ng/mL). Radiolabeled IGF-II (9 +/- 1%) and IGF-I (20 +/- 2%) bound specifically to pheochromocytoma membranes. Western analysis of these membranes using a specific antiserum directed against the type II receptor demonstrated a band at 210 kDa. Affinity cross-linking studies with [125I]IGF-I demonstrated a specific band at 140 kDa. Ligand blot analysis was performed on the void volume pools from the Sephadex G-75 column and demonstrated bands at about 30 and 25 kDa. In conclusion, these data 1) confirm that pheochromocytomas have increased levels of IGF-II; 2) demonstrate that despite high IGF-II concentrations in the tumors, peripheral levels are not elevated, suggesting that very little tumoral IGF-II is released into the circulation, unlike catecholamines; 3) demonstrate the presence of IGF-II and IGF-I receptors; 4) describe binding protein species similar to those present in other tissues. Thus, the presence of high levels of IGF-II and both type I and type II receptors suggests that IGF II may act through both receptors to alter tumor growth.

[1]  K. Shimada,et al.  A case of pheochromocytoma producing parathyroid hormone-related protein and presenting with hypercalcemia. , 1990, The Journal of clinical endocrinology and metabolism.

[2]  K. Yoshinaga,et al.  Immunoreactive corticotropin-releasing hormone, growth hormone-releasing hormone, somatostatin, and peptide histidine methionine are present in adrenal pheochromocytomas, but not in extra-adrenal pheochromocytoma. , 1990, The Journal of clinical endocrinology and metabolism.

[3]  W. Daughaday,et al.  Significance of abnormal serum binding of insulin-like growth factor II in the development of hypoglycemia in patients with non-islet-cell tumors. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[4]  V. Han,et al.  Rat astroglial somatomedin/insulin-like growth factor binding proteins: characterization and evidence of biologic function , 1988, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[5]  R. Baxter,et al.  A comparison of the insulin and insulin-like growth factor I receptors from rat brain and liver. , 1988, Endocrinology.

[6]  D. Clemmons,et al.  An insulin-like growth factor (IGF) binding protein enhances the biologic response to IGF-I. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[7]  V. Han,et al.  Cellular localization of somatomedin (insulin-like growth factor) messenger RNA in the human fetus. , 1987, Science.

[8]  J. Irminger,et al.  Insulin-like growth factor II in human adrenal pheochromocytomas and Wilms tumors: expression at the mRNA and protein level. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[9]  D. Kaufman,et al.  Secretion of an insulin-like growth factor-I-related protein by human breast cancer cells. , 1986, Cancer research.

[10]  M. Binoux,et al.  Analysis of serum insulin-like growth factor binding proteins using western blotting: use of the method for titration of the binding proteins and competitive binding studies. , 1986, Analytical biochemistry.

[11]  Rent,et al.  Insulin-like growth factor II (IGF II) in human brain: regional distribution of IGF II and of higher molecular mass forms. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[12]  T. Sano,et al.  Production of growth hormone-releasing factor in pheochromocytoma. , 1984, The New England journal of medicine.

[13]  A. D'ercole,et al.  Insulin and insulin-like growth factors/somatomedins in fetal and neonatal development. , 1984, Clinics in endocrinology and metabolism.

[14]  M. Kasuga,et al.  Purification of an insulin-like growth factor II receptor from rat chondrosarcoma cells. , 1983, Journal of Biological Chemistry.

[15]  M. Binoux,et al.  Evidence for production by the liver of two IGF binding proteins with similar molecular weights but different affinities for IGF I and IGF II. Their relations with serum and cerebrospinal fluid IGF binding proteins. , 1982, The Journal of clinical endocrinology and metabolism.

[16]  L. Frohman.  Ectopic hormone production. , 1981, The American journal of medicine.

[17]  W. Daughaday,et al.  Inhibition of access of bound somatomedin to membrane receptor and immunobinding sites: a comparison of radioreceptor and radioimmunoassay of somatomedin in native and acid-ethanol-extracted serum. , 1980, The Journal of clinical endocrinology and metabolism.

[18]  T. Hökfelt,et al.  Enkephalin- and somatostatin-like immunoreactivities in human adrenal medulla and pheochromocytoma. , 1979, Proceedings of the National Academy of Sciences of the United States of America.

[19]  U. K. Laemmli,et al.  Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4 , 1970, Nature.

[20]  M. Rechler,et al.  Insulin-Like Growth Factors , 1991 .

[21]  M. Rechler,et al.  [25] Purification of rat insulin-like growth factor II , 1987 .

[22]  R. Baxter.  The somatomedins: insulin-like growth factors. , 1986, Advances in clinical chemistry.